+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Estrogen and progesterone receptors of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen



Estrogen and progesterone receptors of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen



Gynecologic and Obstetric Investigation 45(2): 126-131



Adenomyosis is an ectopic endometrial tissue located in the myometrium. It has been reported to develop at a higher rate among postmenopausal breast cancer patients on tamoxifen (TAM) treatment than in untreated patients. It has also been reported to be stimulated by estrogen. Assessing receptor levels in adenomyotic tissue may indicate the adenomyotic cell's potential to interact with TAM. In the present study the estrogen receptor (ER) and progesterone receptor (PR) were analyzed by an immunohistochemical technique in adenomyotic and the corresponding endometrial tissues of 14 postmenopausal breast cancer patients treated with TAM and in 15 healthy postmenopausal patients who served as controls. All TAM-treated patients had normal postmenopausal serum estradiol levels. Overall the ER and PR contents in adenomyotic tissue (42.9 and 71.4%) and in the endometriotic tissue (64.3 and 78.6%) obtained from the study patients were similar to those obtained from the control group (adenomyosis, ER and PR = 46.7 and 86.7%; endometrium, ER and PR = 40 and 73.3%; p = NS). In the study group, the ER content was lower in the adenomyotic (42.9%) than in the endometriotic tissue (64.3%). No correlation was found between the duration of TAM therapy, the TAM dosage level or the ER or PR content in the adenomyotic or endometrial tissues. The finding of a relatively low ER content in the adenomyotic tissue than in the endometriotic tissue in postmenopausal TAM-treated patients without endogenous estrogens, similar to that observed in healthy premenopausal women, may be attributed to the estrogen-like effect of TAM.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 008627107

Download citation: RISBibTeXText

PMID: 9517806


Related references

Estrogen and Progesterone Receptors of Adenomyosis in Postmenopausal Breast Cancer Patients Treated with Tamoxifen. Gynecologic and Obstetric Investigation 45(2): 126-131, 1998

Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens. Gynecologic Oncology 65(1): 83-88, 1997

Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity?. Gynecologic Oncology 58(1): 86-91, 1995

Estrogen and Progesterone Receptors in Benign Ovarian Tumors of Menopausal Breast Cancer Patients Treated with Tamoxifen. Gynecologic and Obstetric Investigation 46(2): 116-122, 1998

Estrogen and progesterone receptors in benign ovarian tumors of menopausal breast cancer patients treated with tamoxifen. Gynecologic and Obstetric Investigation 46(2): 116-122, 1998

High frequency of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen. Gynecologic and Obstetric Investigation 44(3): 200-205, 1997

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. Journal of Clinical Oncology 25(25): 3846-3852, 2007

Expression of hormonal receptors (alpha-estrogen, beta-estrogen, progesteron), Ki-67 and P53 in endometrium of tamoxifen treated breast cancer patients. Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 115(3): 834-838, 2012

Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen. International Journal of Biological Markers 13(1): 30-41, 1998

Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer. Cancer Research 41(5): 1984-1988, 1981

Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen. Seminars in Oncology 15(2 Suppl 1): 26-33, 1988

Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. European Journal of Cancer 50(8): 1412-1421, 2014

Tamoxifen therapy in advanced breast cancer with positive estrogen receptors in postmenopausal women. Tumori 68(2): 143-148, 1982

Effects of low-dose tamoxifen on breast cancer biomarkers Ki-67, estrogen and progesterone receptors. International Seminars in Surgical Oncology 3: 29, 2006

Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecologic Oncology 52(2): 185-190, 1994